Summary: OVERPRICED
Score: 2/20
MOS: 0%
Share Price: $173
Sticker Price: $0
Is Novavax a good buy?
Novavax is a small vaccine development company headquartered in Gaithersburg, MD, with additional facilities in Rockville, Maryland and Uppsala, Sweden. They were founded in 1987 and currently have about 375 employees. As of 2020, it has an ongoing Phase III clinical trial in older adults for its candidate vaccine for seasonal influenza, NanoFlu and a candidate vaccine for prevention of COVID-19.
We’re heading into another speculative wave. History likes to repeat itself and human emotions are starting to attached to a new shiny object.
Remember the cryptocurrency craze at the end of 2017? Bitcoin hit an all time high of close to $20,000 per coin and now Bitcoin is at $11,000 per coin. A 45% drop.
How about the marijuana stock craze in 2018? Canopy Growth (CGC) hit an all time of $51 in 2018 and now the stock is at $16. A 68% drop. Aurora (ACB) hit an all time high of $128 and now the stock is at $10. A 92% drop.
We’re heading into another craze with potential COVID-19 vaccines and the list of companies working on a solution keeps growing.
Before I talk more about Novavax, I will say that I give these companies a lot of credit. They are trying to solve a major problem and I respect them for that. On the flip side of that coin, I cannot make a investment because I don’t invest in speculation.
With a score of 2/20, the financials are very weak. This would be a very risky investment. Also note the share price of $173 and a sticker price of $0. This stock could nose dive to single digits or close to, similar to the marijuana stocks.
—
The Summary, Score, and MOS of this stock may have changed since the posting of this review. Please login to Tykr to see up-to-date information.